Our Science

Our Science

T cells are central players in the adaptive immune system.

Together, these T cells are essential for clearing infections, shaping immune memory, and providing long-term protection.

Research led by our team has significantly advanced our understanding of T cells, particularly in the context of viral infections. Our work has shown that strong CD8⁺ T cell responses are associated with milder disease outcomes in infections like COVID-19, emphasising their role in protective immunity.

Why Measure T Cells
Challenges in T Cells Testing
Innovation
Clinical Applications
Why Measure T Cells
Why Measure T Cells
Challenges in T Cells Testing
Innovation
Clinical Applications

To overcome these barriers, T Cell Diagnostics propose the Whole-Blood Cytokine Release Assay (CRA)—a simple, scalable, and clinically validated method for measuring antigen-specific T cell responses.

Key advantages of the CRA:

Less than 1 mL of fresh whole blood

Direct stimulation with pathogen-specific peptide pools

Multiplex readout:

Detects cytokines (e.g., interferon-γ, IL-2) secreted by antigen-specific T cells

This streamlined approach eliminates the need for complex cell processing, enabling T cell monitoring in both research and clinical settings.

The Whole-Blood CRA combines simplicity, efficiency, speed, and insight to deliver practical T cell testing with proven clinical impact:

Chronic Hepatitis B

Identified functional T cell responses in ~80% of patients, supporting patient stratification, disease monitoring, and treatment optimisation.

Tracked engineered T cell activity in patients receiving HBV-specific TCR therapy with Lion TCR Pte Ltd, providing real-time treatment assessment.

Detection of virus-specific T-cell responses to SARS-CoV-2, dengue, HCMV, and influenza, enabling population-scale immune monitoring.

By making T cell diagnostics accessible and actionable, the CRA is redefining immune monitoring in infectious disease, immunotherapy, and vaccine development.

Conventional T cell assays, such as ELISpot or flow cytometry, are technically demanding and challenging to implement in routine clinical settings. These methods typically require:

Labour-intensive preparation limits practicality.

Complex procedures need trained staff and controlled environments.

Time-consuming protocols

Multi-step workflows can take hours to days, resulting in delayed results.

These logistical and technical hurdles have significantly constrained the adoption of T cell testing in routine diagnostics, preventing its full potential from being realised in patient care, immunotherapy monitoring, and large-scale disease surveillance.

Antibody tests provide only a partial view of immunity. T cells provide critical, complementary insights, especially in the context of chronic infections and vaccination.

In diseases such as hepatitis B (HBV) and COVID-19, antibody levels don’t always correlate with T cell responses. T cell immunity can persist even when antibodies wane, highlighting the importance of assessing both arms of the immune system.

Assessing T cell responses can:

Detect immune dysfunction in chronic infections and guide treatment.